Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- betrixaban
- Bridion (sugammadex)
Interactions between your drugs
sugammadex betrixaban
Applies to: Bridion (sugammadex), betrixaban
MONITOR: Sugammadex may potentiate the effects of anticoagulants. The mechanism of interaction has not been described. In healthy volunteers, sugammadex doses up to 16 mg/kg were associated with increases in activated partial thromboplastin time (aPTT) and prothrombin time (PT)/international normalized ratio (INR) of up to 25% for up to one hour. In a clinical trial of patients undergoing major orthopedic surgery of the lower extremity who received heparin or low molecular weight heparin (LMWH) for thromboprophylaxis, increases in aPTT and PT/INR of 5.5% and 3.0%, respectively, were observed in the hour following administration of a 4 mg/kg sugammadex dose. The changes in coagulation parameters were not associated with an increased incidence of blood loss or anemia; however, a higher dosage of sugammadex may produce clinically significant effects. In vitro, additional aPTT and PT/INR prolongations of up to approximately 25% and 50% were demonstrated when sugammadex was combined with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran at peak levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively.
MANAGEMENT: Hemostasis and coagulation parameters should be closely monitored when sugammadex is administered to patients receiving therapeutic anticoagulation for a preexisting or comorbid condition; patients who have received thromboprophylaxis drugs other than heparin and LMWH; or patients who have received thromboprophylaxis with heparin or LMWH and subsequently administered 16 mg/kg of sugammadex.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2015) "Product Information. Bridion (sugammadex)." Merck & Co., Inc
Drug and food interactions
betrixaban food
Applies to: betrixaban
ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.
MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.
References (1)
- (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Pradaxa
Pradaxa (dabigatran) is used to prevent stroke and blood clots in patients with atrial ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Fragmin
Fragmin is an anticoagulant used to prevent blood clots such as deep vein thrombosis, which can ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Edoxaban
Edoxaban is used for atrial fibrillation, deep vein thrombosis, prevention of thromboembolism in ...
Fondaparinux
Fondaparinux is used for deep vein thrombosis, deep vein thrombosis prophylaxis after abdominal ...
Rivaroxaban
Rivaroxaban is used for atrial fibrillation, cardiovascular risk reduction, congenital heart ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.